Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

301 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group.
von Minckwitz G, Raab G, Caputo A, Schütte M, Hilfrich J, Blohmer JU, Gerber B, Costa SD, Merkle E, Eidtmann H, Lampe D, Jackisch C, du Bois A, Kaufmann M. von Minckwitz G, et al. Among authors: schutte m. J Clin Oncol. 2005 Apr 20;23(12):2676-85. doi: 10.1200/JCO.2005.05.078. J Clin Oncol. 2005. PMID: 15837982 Clinical Trial.
Dose-dense biweekly doxorubicin/docetaxel versus sequential neoadjuvant chemotherapy with doxorubicin/cyclophosphamide/docetaxel in operable breast cancer: second interim analysis.
Jackisch C, von Minckwitz G, Eidtmann H, Costa SD, Raab G, Blohmer JU, Schütte M, Gerber B, Merkle E, Gademann G, Lampe D, Hilfrich J, Tulusan AH, Caputo A, Kaufmann M. Jackisch C, et al. Among authors: schutte m. Clin Breast Cancer. 2002 Oct;3(4):276-80. doi: 10.3816/cbc.2002.n.031. Clin Breast Cancer. 2002. PMID: 12425756 Clinical Trial.
Clinical response by palpation during primary systemic therapy with four dose-dense cycles doxorubicin and docetaxel in patients with operable breast cancer: further results from a randomised controlled trial.
Müller C, Caputo A, Schumacher M, Raab G, Schütte M, Hilfrich J, Kaufmann M, von Minckwitz G. Müller C, et al. Among authors: schutte m. Eur J Cancer. 2007 Jul;43(11):1654-61. doi: 10.1016/j.ejca.2007.04.020. Epub 2007 Jun 4. Eur J Cancer. 2007. PMID: 17544652 Clinical Trial.
[Preoperative chemotherapy in primary operable breast cancer with a dose-dense combination of doxorubicin and docetaxel (ADoc) - Experience of the GEPARDO-GABG study group].
von Minckwitz G, Raab G, Schütte M, Hilfrich J, Blohmer JU, Gerber B, Costa SD, Merkle E, Eidtmann H, Lampe D, Jackisch C, du Bois A, Tulusan AH, Gademann G, Sinn HP, Caputo A, Graf E, Kaufmann M. von Minckwitz G, et al. Among authors: schutte m. Zentralbl Gynakol. 2001 Sep;123(9):497-504. doi: 10.1055/s-2001-18222. Zentralbl Gynakol. 2001. PMID: 11709742 Review. German.
Evaluation of the importance and relevance of dose intensity using epirubicin and cyclophosphamide in metastatic breast cancer: interim analysis of a prospective randomized trial.
Marschner N, Kreienberg R, Souchon R, Räth U, Eggeling B, Voigtmann R, Ruffert K, Schütte M, Ammon A, Kesztyüs T, et al. Marschner N, et al. Among authors: schutte m. Semin Oncol. 1994 Feb;21(1 Suppl 1):10-6. Semin Oncol. 1994. PMID: 8153652 Clinical Trial. No abstract available.
FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients.
Fasching PA, Jud SM, Hauschild M, Kümmel S, Schütte M, Warm M, Hanf V, Grab D, Krocker J, Stickeler E, Kreienberg R, Müller T, Kühn T, Wolf C, Kahlert S, Paepke S, Berghorn M, Muth M, Baier M, Wackwitz B, Schulz-Wendtland R, Beckmann MW, Lux MP. Fasching PA, et al. Among authors: schutte m. BMC Cancer. 2014 Feb 5;14:66. doi: 10.1186/1471-2407-14-66. BMC Cancer. 2014. PMID: 24499441 Free PMC article. Clinical Trial.
Phase II trial of vinorelbine and trastuzumab in patients with HER2-positive metastatic breast cancer. A prospective, open label, non-controlled, multicenter phase II trial (to investigate efficacy and safety of this combination chemotherapy).
Schilling G, Bruweleit M, Harbeck N, Thomssen C, Becker K, Hoffmann R, Villena C, Schütte M, Hossfeld DK, Bokemeyer C, de Wit M. Schilling G, et al. Among authors: schutte m. Invest New Drugs. 2009 Apr;27(2):166-72. doi: 10.1007/s10637-008-9166-8. Epub 2008 Aug 12. Invest New Drugs. 2009. PMID: 18696011 Clinical Trial.
Drug-polymer conjugates containing acid-cleavable bonds.
Kratz F, Beyer U, Schütte MT. Kratz F, et al. Among authors: schutte mt. Crit Rev Ther Drug Carrier Syst. 1999;16(3):245-88. doi: 10.1615/critrevtherdrugcarriersyst.v16.i3.10. Crit Rev Ther Drug Carrier Syst. 1999. PMID: 10706520 Review.
301 results